Comparative Pharmacology
Head-to-head clinical analysis: AZASITE versus BIAXIN XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZASITE versus BIAXIN XL.
AZASITE vs BIAXIN XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azasite (azithromycin ophthalmic solution) is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis.
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
1 drop of 1% ophthalmic solution to each affected eye twice daily (approximately 12 hours apart) for 2 days, then once daily for 5 days.
500 mg orally once daily for 7 to 14 days
None Documented
None Documented
Terminal elimination half-life: 68-72 hours; facilitates once-weekly dosing for trachoma.
Terminal elimination half-life is 5-7 hours in healthy adults; prolonged to 20-40 hours in patients with severe hepatic impairment (Child-Pugh Class C).
Primarily hepatic/biliary (fecal) as unchanged drug: ~70% fecal, ~20% renal (mostly unchanged), ~0.5% urinary as metabolites.
Approximately 20-30% of the dose is excreted unchanged in urine, with the remainder as metabolites (primarily via biliary/fecal elimination). Renal clearance accounts for about 12% of total clearance.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic